Physician profile
Mark R Honzel
NPI 1083761670
$27,263.49
in general payments reported to CMS, 2019-2025
59 companies · $5,231 in 2025
The $5,231 reported for 2025 was more than what 93% of Addiction Medicine (Internal Medicine) providers received nationally (typical 2025 total: $124).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,621 · 2020: $2,878 · 2021: $4,512 · 2022: $3,039 · 2023: $4,162 · 2024: $4,821 · 2025: $5,231.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $14K · Education: $11.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $14,201.47 |
| Education | $11.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $3,351.51 | 2019-2025 | |
| Gilead Sciences, INC. | $2,635.67 | 2019-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $2,024.05 | 2020-2025 | Caplyta |
| Lundbeck LLC | $1,870.92 | 2019-2025 | Rexulti, Abilify Maintena |
| Viiv Healthcare Company | $1,863.33 | 2019-2025 | Dovato, Apretude, Cabenuva |
| Takeda Pharmaceuticals U.S.A., INC. | $1,504.56 | 2019-2025 | Trintellix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,394.94 | 2019-2025 | Relistor, Xifaxan, Trulance |
| Vanda Pharmaceuticals INC. | $1,309.22 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $1,113.19 | 2019-2025 | Invega Sustenna, Spravato |
| Otsuka America Pharmaceutical, INC. | $1,077.82 | 2019-2025 | Rexulti, Abilify Maintena, Abilify Asimtufii |
| Axsome Therapeutics, INC. | $915.84 | 2022-2025 | Auvelity, Sunosi |
| Alkermes, INC. | $794.32 | 2019-2025 | Aristada, Lybalvi |
| Indivior INC. | $680.39 | 2019-2025 | Sublocade |
| Almatica Pharma LLC | $590.99 | 2021-2025 | Loreev Xr, Gralise, Sertraline Hcl |
| Sunovion Pharmaceuticals INC. | $584.27 | 2019-2022 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Emd Serono, INC. | $514.08 | 2019-2025 | Serostim |
| Theratechnologies INC. | $446.27 | 2019-2024 | Egrifta, Trogarzo |
| Neurocrine Biosciences, INC. | $408.51 | 2019-2025 | |
| Napo Pharmaceuticals INC | $390.46 | 2019-2025 | Mytesi |
| Idorsia Pharmaceuticals US INC | $363.36 | 2022-2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $320.19 | 2023-2025 | Uzedy |
| Merck Sharp & Dohme LLC | $305.17 | 2019-2025 | Pifeltro, Delstrigo, Dificid |
| Janssen Biotech, INC. | $297.89 | 2019-2023 | Symtuza |
| Bausch Health US, LLC | $248.66 | 2021-2025 | Aplenzin, Wellbutrin |
| Orexo US, INC. | $189.65 | 2019-2021 | |
| Neuronetics, INC. | $183.09 | 2021-2023 | Neurostar Tms Therapy System |
| Allergan, INC. | $168.33 | 2019-2020 | |
| Lilly USA, LLC | $154.05 | 2019-2025 | Mounjaro, Zepbound |
| Amgen INC. | $137.41 | 2023-2025 | Otezla, Repatha, Repatha |
| Supernus Pharmaceuticals, INC. | $115.13 | 2022-2025 | Qelbree |
| Braeburn INC. | $110.52 | 2024 | Brixadi |
| Astrazeneca Pharmaceuticals Lp | $106.71 | 2019-2023 | Breztri, Farxiga |
| Antares Pharma, INC. | $104.63 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Luye Pharma (USA) Ltd. | $88.12 | 2025 | Erzofri Extended-Release |
| Biohaven Pharmaceuticals, INC. | $85.71 | 2021 | |
| Tris Pharma INC | $84.82 | 2023 | Dyanavel Xr |
| E.R. Squibb & Sons, L.L.C. | $76.62 | 2024-2025 | Cobenfy |
| Adlon Therapeutics L.P. | $70.84 | 2020-2021 | |
| Grifols USA, LLC | $56.74 | 2024-2025 | Gamunex-C, Xembify |
| Eisai INC. | $51.53 | 2020-2021 | |
| Tolmar, INC. | $44.08 | 2025 | Jatenzo |
| Jazz Pharmaceuticals INC. | $37.63 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $33.10 | 2024 | Synjardy, Tradjenta, Jardiance |
| Uswm, LLC | $32.97 | 2022 | |
| Alfasigma USA, INC. | $32.04 | 2020-2021 | |
| Vertical Pharmaceuticals, LLC | $30.48 | 2019 | |
| Scilex Pharmaceuticals INC. | $24.82 | 2020 | |
| Redhill Biopharma INC. | $24.80 | 2021 | |
| Valinor Pharma, LLC | $22.73 | 2023 | Movantik |
| Noven Therapeutics, LLC | $21.53 | 2021 | |
| Argenx US, INC. | $21.10 | 2025 | Vyvgart Hytrulo |
| Acerus Pharmaceuticals Corporation | $21.02 | 2022 | |
| Owp Pharmaceuticals, INC. | $20.19 | 2022 | |
| Mdd US Operations, LLC | $19.80 | 2019 | |
| Astellas Pharma US INC | $18.84 | 2021 | |
| Novo Nordisk INC | $18.10 | 2021 | |
| Optos, INC. | $17.58 | 2021 | |
| Aytu Biopharma, INC. | $16.73 | 2020 | |
| Biodelivery Sciences International, INC. | $16.44 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Honzel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.